Financials data is unavailable for this security.
View more
Year on year Pfizer Ltd 's revenues fell -9.55%from 24.25bn to 21.93bn. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a -11.64% reduction in net income from 6.24bn to 5.51bn.
| Gross margin | 65.00% |
|---|---|
| Net profit margin | 27.61% |
| Operating margin | 29.30% |
| Return on assets | 14.60% |
|---|---|
| Return on equity | 17.59% |
| Return on investment | 17.05% |
More ▼
Cash flow in INRView more
In 2024, Pfizer Ltd increased its cash reserves by 206.01%, or 754.00m. The company earned 2.57bn from its operations for a Cash Flow Margin of 11.71%. In addition the company generated 537.00m cash from investing, though they paid out 2.35bn more in financing than they received.
| Cash flow per share | 148.37 |
|---|---|
| Price/Cash flow per share | 35.44 |
| Book value per share | 819.90 |
|---|---|
| Tangible book value per share | 698.20 |
More ▼
Balance sheet in INRView more
| Current ratio | 5.05 |
|---|---|
| Quick ratio | 4.30 |
| Total debt/total equity | 0.0275 |
|---|---|
| Total debt/total capital | 0.0267 |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -11.64%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.72% |
|---|---|
| Div growth rate (5 year) | 9.24% |
| Payout ratio (TTM) | 25.91% |
| EPS growth(5 years) | 5.14 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 18.19 |
More ▼
